RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global Healthcare Conference – Miami, FLJoe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th. Joe Ciaffoni will also participate in a fireside chat on Tuesday, March 10th at 2:00 p.m. U.S. EST. Interested investors should contact their Barclays representative to sche ...

PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS) 24 February 2026 – Theon International Plc (THEON) (ISIN: CY0200751713) entered on 21st January 2026, into a Liquidity Contract with Kepler Cheuvreux (the "Liquidity Agreement"). Under the Liquidity Agreement, an initial amount of €1 million and 33,000 Shares were made available to Kepler Cheuvreux, to enhance the liquidity of the Shares in THEON on the regulated market of Euronext Amsterdam. On February 18, 2026, Parties have agreed that THEON will m ...

MONTRÉAL, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OR Royalties Inc. (“OR Royalties” or the “Company”) (OR: TSX & NYSE) is pleased to announce that it has entered into a definitive agreement to acquire Terraco Gold Corp. (“Terraco”), a wholly-owned subsidiary of Sailfish Royalty Corp., which indirectly owns net smelter return (“NSR”) royalty assets (the “NSR Royalties”), largely consisting of royalties that cover Solidus Resources LLC’s (“Solidus”) Spring Valley Gold Project (“Spring Valley” or the “Project”) loca ...

Core Viewpoint - BioNTech SE will announce its financial results for Q4 and full year 2025 on March 10, 2026, and will host a conference call and webcast for stakeholders to discuss these results and provide a corporate update [1]. Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and other serious diseases, utilizing a variety of computational discovery and therapeutic modalities [4]. - The company has a diversified portfolio of oncology product candidates, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies [4]. - BioNTech is also researching and developing multiple mRNA vaccine candidates for various infectious diseases, leveraging its expertise in mRNA development and in-house manufacturing capabilities [4]. - The company has established partnerships with several global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Pfizer, and Genentech, among others [4].

WILMINGTON, Del., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Global Indemnity Group, LLC (NASDAQ:GBLI) (“GBLI”) announced today that it will release its 2025 earnings results before market open on Tuesday, March 10, 2026. GBLI will hold an earnings call to discuss 2025 results on Tuesday, March 10, 2026 at 11:00 a.m. Eastern. The earnings call will be webcast on GBLI’s website at www.gbli.com. To participate via telephone, please register in advance using this link, https://register-conf.media-server.com/register/BI ...

THE WOODLANDS, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today announced the timing of its fourth quarter and full year 2025 earnings release and conference call. Ring plans to issue its fourth quarter and full year 2025 earnings release after the close of trading on Wednesday, March 4, 2026. The Company has scheduled a conference call on Thursday, March 5, 2026 at 11:00 a.m. ET (10:00 a.m. CT) to discuss its fourth quarter and full year 2025 o ...

Core Insights - Bimergen Energy Corporation has received formal approval for its Redbird project, a 100 MW / 400 MWh battery energy storage system in Texas, under its Joint Development Agreement [1][2] - The project will utilize Eos Energy Enterprises' Z3™ zinc-based battery technology, enhancing its execution towards commercial operations in the ERCOT market [1][2] Company Overview - Bimergen Energy Corporation is a U.S.-based independent power producer focused on utility-scale battery energy storage systems, managing the entire project lifecycle from development to operations [5] - The company aims to provide grid reliability, renewable integration, and flexible energy solutions through its battery energy storage systems [5] Project Details - The Redbird BESS is designed to offer dispatchable storage capacity, improving grid reliability and supporting renewable energy integration [3] - The project is crucial for maintaining system stability in Texas, which is experiencing rapid load growth due to economic expansion and population increases [3] Strategic Importance - The approval and technology selection signify a major advancement for Bimergen, reflecting its commitment to safe and reliable multi-hour storage solutions [4] - The project is expected to deliver long-term value and enhance grid resilience across ERCOT, addressing the growing demand for dependable energy storage [4]

Core Insights - Palvella Therapeutics announced positive topline results from the Phase 3 SELVA study of QTORIN™ rapamycin for treating microcystic lymphatic malformations, meeting its primary endpoint with a statistically significant improvement [2][3] - The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026, with potential approval in the first half of 2027 [3][10] Study Results - The primary endpoint, the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA), showed a mean improvement of +2.13 points (p<0.001) [5][6] - 95% of participants aged ≥ 6 who completed the efficacy evaluation improved on the mLM-IGA at Week 24, with 86% rated as "Much Improved" or "Very Much Improved" [6][9] - All four secondary efficacy endpoints also achieved statistical significance (all p<0.001) [2][5] Safety and Tolerability - QTORIN™ rapamycin was well-tolerated, with no drug-related serious adverse events reported and systemic rapamycin levels below 2 ng/mL at all timepoints [6][8] - Among the 50 participants, 70% experienced treatment-emergent adverse events, but all were rated mild or moderate [8][9] Future Plans - Palvella aims to present detailed results from the SELVA study at upcoming medical meetings and is advancing QTORIN™ rapamycin for other rare skin diseases [11] - The company has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA for QTORIN™ rapamycin [10]

Core Insights - CECO Environmental and Thermon Group have announced a definitive agreement to combine in a transaction valued at approximately $2.2 billion, which will enhance CECO's capabilities in industrial process heating and thermal management [1][2][4] Company Overview - CECO Environmental is a diversified industrial company focused on environmentally friendly solutions, while Thermon is a leader in industrial process heating and temperature management [13][14] - The combined company will operate under the CECO Environmental name and will be led by CEO Todd Gleason, with two members from Thermon's board joining CECO's board [1][8] Strategic Benefits - The merger is expected to create a world-class industrial solutions platform, enhancing CECO's leadership in industrial environmental and thermal solutions [2][4] - The combination will provide a comprehensive platform of industrial solutions, addressing critical areas such as thermal and acoustic management, emissions control, and industrial air quality [4][5] Financial Aspects - The transaction will be funded through a mix of cash and stock, with Thermon shareholders having multiple options for consideration, including a mixed option valued at approximately $63.13 per share, representing a 26.8% premium over Thermon's closing stock price [6][7] - The combined entity is projected to generate approximately $40 million in annual cost synergies within 36 months, enhancing its financial profile and resilience [11] Market Position and Growth - The merger positions the combined company to capitalize on durable secular trends such as energy transition, decarbonization, and tightening environmental regulations, which are expected to drive long-term growth [2][11] - The integration of both companies is anticipated to accelerate growth through expanded customer relationships and global reach [2][4]

Company Announcement Copenhagen, 24 February 2026 No. 12/2026 Acquisition of ISS A/S shares by Members of the Board of DirectorsISS A/S, a leading workplace experience and facility management company, has received notification pursuant to article 19 of the Market Abuse Regulation of transactions in ISS A/S’ shares made by persons discharging managerial responsibilities in ISS A/S and/or their closely associated persons. Member of the Board of Directors Henriette Hallberg Thygesen has purchased 3,000 shares ...